Debon securities issued a research report on April 30, giving Lushang Health Industry Development Co.Ltd(600223) ( Lushang Health Industry Development Co.Ltd(600223) .sh, latest price: 8.55 yuan) a buy rating. The reasons for rating mainly include: 1) the company released the first quarterly report of 22 years, and the real estate business disturbed the scale of revenue; 2) The adjustment of sales structure promoted the significant increase of gross profit margin; 3) Cosmetics: “4 + n” operation continues the high growth trend. Risk tips: there is a risk of declining prosperity in the cosmetics industry, increased competition in the cosmetics industry, the promotion of new products is less than expected, and the real estate policy is tightened.
AI comments: Lushang Health Industry Development Co.Ltd(600223) has received attention from 10 research reports of securities companies in the past month, including 7 purchases and 2 holdings. The average target price is 11.1 yuan, 2.55 yuan higher than the latest price of 8.55 yuan, and the average target price increases by 29.82%.
